GlassScriptPhysician profile
Rosalyn M Morrell
NPI 1700871860
$3,008.56
in general payments reported to CMS, 2019-2025
41 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $50.40 · 2022: $60.14 · 2023: $348 · 2024: $17.22 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $445.44 | 2022-2025 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $323.86 | 2019-2025 | Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $212.35 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.70 | 2019-2025 | Fruzaqla |
| Stemline Therapeutics INC. | $117.66 | 2025 | Orserdu |
| Celgene Corporation | $113.94 | 2019 | |
| Eisai INC. | $111.48 | 2019 | |
| Incyte Corporation | $94.36 | 2019-2025 | Jakafi |
| Ge Healthcare | $87.81 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $85.12 | 2019-2025 | Onivyde |
| Tersera Therapeutics LLC | $82.30 | 2019-2025 | Quzyttir |
| Jazz Pharmaceuticals INC. | $73.53 | 2025 | |
| Janssen Biotech, INC. | $71.68 | 2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $57.55 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalyn Morrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.